Why Medicare Spending on Alzheimer’s Drugs Remains Lower Than Projected

Recent projections regarding Medicare Part B spending on new monoclonal antibody treatments for Alzheimer’s disease, such as lecanemab and donanemab, have significantly overestimated the actual financial impact on the program. While initial reports warned of a potential fiscal crisis, the anticipated surge in expenditures has not materialized, resulting in a surprising budgetary relief for CMS. This paradox is primarily attributed to the complex logistical hurdles and administrative friction inherent in the current healthcare delivery system rather than a lack of patient demand. Administering these high-maintenance therapies requires a robust, integrated clinical infrastructure that is currently fragmented, which has inadvertently acted as a bottleneck to widespread adoption. As healthcare providers navigate these rigorous diagnostic and treatment protocols, the pace of drug integration remains slower than analysts originally forecasted. This situation highlights the disconnect between breakthrough pharmaceutical innovation and the systemic capacity of the Medicare framework to absorb high-stakes, specialized medicine, ultimately creating an unexpected, if temporary, stability for Medicare trust funds amidst ongoing long-term sustainability concerns.